Philogen SpA (PHIL) AI Stock Analysis

• Market Cap: €681.36M
• Dividend Yield: N/A
• Average Volume (3M): 15.32K
• Price to Earnings (P/E): 20.6
• Beta (1Y): -0.10
• Revenue Growth: 219.91%
• EPS Growth: N/A
• Country: IT
• Employees: 174
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 5.53
• Shares Outstanding: 29,242,860
• 10 Day Avg. Volume: 15,647
• 30 Day Avg. Volume: 15,317
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €29.00
• Price Target Upside: 25.54% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 70 Outperform
• Price Target: €25.00 ▲(8.23% Upside)

Philogen SpA's strong financial performance is the most significant factor, supported by robust revenue growth and improved profitability. Technical analysis presents mixed signals, with some short-term weakness. The valuation is reasonable, though the lack of a dividend yield may deter some investors.

Positive Factors

Negative Factors

Philogen SpA Business Overview & Revenue Model

Company Description

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase I clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. Philogen S.p.A. was founded in 1996 and is based in Sovicille, Italy.

How the Company Makes Money

Philogen SpA generates revenue primarily through the development and commercialization of its biopharmaceutical products. The company's revenue streams include licensing agreements, where they collaborate with larger pharmaceutical companies to further develop and market their drug candidates. Philogen may receive upfront payments, milestone payments based on the progress of clinical trials and regulatory approvals, and royalties on sales of successfully commercialized products. Additionally, the company may engage in research and development collaborations and partnerships that provide funding and shared resources, contributing to its earnings. Philogen's focus on developing targeted therapies allows it to position itself in niche markets with high unmet medical needs, potentially leading to premium pricing for its innovative treatments.

Philogen SpA Financial Statement Overview

Summary

Philogen SpA demonstrates excellent financial performance in 2024, with significant revenue growth, improved margins, and a strong balance sheet with no debt. Cash flows are robust, supporting operational and investment activities. The overall financial health is solid, positioning the company well for future growth.

Income Statement

Philogen SpA shows strong revenue growth with a significant increase from €23.1M in 2023 to €77.6M in 2024. The gross profit margin improved drastically from 24.5% in 2023 to 53.6% in 2024. The company turned profitable with a net profit margin of 58.3% in 2024, a remarkable recovery from previous losses. EBIT and EBITDA margins also improved to 53.6% in 2024, reflecting efficient cost management.

Balance Sheet

The balance sheet is strong with no debt in 2024, improving the debt-to-equity ratio to 0. The equity ratio is robust at 88.4%, indicating a solid equity base. However, the total assets increased less significantly compared to equity, which may limit leverage opportunities.

Cash Flow

Philogen's free cash flow turned positive in 2024, with a substantial increase to €38.7M from a negative position in 2023. The operating cash flow to net income ratio is 0.90, indicating efficient cash generation relative to net earnings. The free cash flow to net income ratio is 0.85, showing strong cash flow management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	74.00M	23.13M	23.71M	2.50M	4.78M
Gross Profit	54.42M	5.67M	10.53M	-8.14M	-5.05M
EBITDA	44.75M	-2.05M	-1.19M	-12.98M	-10.53M
Net Income	45.29M	-6.16M	-5.38M	-15.72M	-13.29M
Balance Sheet
Total Assets	168.45M	119.27M	125.83M	132.75M	85.47M
Cash, Cash Equivalents and Short-Term Investments	113.73M	75.34M	86.20M	101.68M	61.94M
Total Debt	11.51M	14.91M	11.89M	11.84M	11.98M
Total Liabilities	29.80M	28.68M	27.91M	27.67M	29.80M
Stockholders Equity	138.66M	90.59M	97.92M	105.09M	55.67M
Cash Flow
Free Cash Flow	38.67M	-10.69M	-9.15M	-25.85M	-16.81M
Operating Cash Flow	40.84M	-4.82M	-4.94M	-19.03M	-13.16M
Investing Cash Flow	-22.28M	159.00K	24.20M	-47.77M	17.77M
Financing Cash Flow	-3.78M	-4.17M	-3.78M	63.05M	3.79M

Philogen SpA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 23.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHIL, the sentiment is Positive. The current price of 23.1 is above the 20-day moving average (MA) of 23.01, above the 50-day MA of 22.69, and above the 200-day MA of 21.03, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 53.37 is Neutral, neither overbought nor oversold. The STOCH value of 89.32 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:PHIL.

Philogen SpA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHN	73 Outperform	395.47M	23.22	26.72%	2.49%	13.75%	16.66%
PHIL	70 Outperform	€681.36M	20.55	39.51%	―	219.91%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Philogen SpA Corporate Events

Philogen S.p.A. Updates on Share Buyback Program

Philogen S.p.A. has announced an update on its share buyback program, revealing the purchase of 2,000 shares, equating to 0.0049% of its share capital, at an average price of Euro 22.4727 per share. This move is part of a broader strategy to enhance shareholder value, with the company having acquired a total of 29,448 shares since the program’s inception. The buyback reflects Philogen’s confidence in its market position and commitment to its stakeholders, potentially impacting its financial standing and investor perception.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR26.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen Finalizes $1.35 Billion OncoACP3 License Agreement with RayzeBio

Philogen S.p.A. announced that its subsidiary, Philochem AG, has finalized a license agreement with RayzeBio, a Bristol-Myers Squibb subsidiary, for the therapeutic and diagnostic agent OncoACP3, aimed at treating prostate cancer. The agreement, effective following U.S. antitrust approval, includes an initial payment of $350 million to Philochem, with potential milestone payments up to $1 billion and royalties. This partnership is expected to enhance Philogen’s position in the biotechnology sector and advance RayzeBio’s leadership in radiopharmaceuticals, potentially revolutionizing prostate cancer treatment.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR33.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen Updates Share Buyback Program with Recent Purchases

Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 4,373 shares from June 30 to July 4, 2025, at an average price of Euro 21.4587 per share, totaling Euro 93,838.90. Since the program’s inception, the company has acquired 27,448 shares, representing 0.0676% of its share capital, with a total expenditure of Euro 612,402.32. This strategic move is part of Philogen’s efforts to enhance shareholder value and reflects its ongoing commitment to optimizing its capital structure.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR33.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen Updates Share Buyback Program with Recent Purchases

Philogen S.p.A. has announced an update on its share buyback program, purchasing 8,333 shares between June 23 and June 27, 2025, at an average price of Euro 22.9635 per share. This move reflects the company’s ongoing strategy to manage its share capital and potentially enhance shareholder value, as it now holds 355,225 ordinary shares, representing 0.8747% of its share capital.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR33.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen Withdraws Nidlegy™ Application from EMA, Plans Resubmission

Philogen has decided to withdraw its marketing authorization application for Nidlegy™, a treatment for locally advanced melanoma, from the European Medicines Agency due to delays in providing necessary data. Despite this setback, Philogen remains confident in Nidlegy™’s efficacy and safety profile, and plans to resubmit the application with updated data to make the treatment available for both melanoma and non-melanoma skin cancer patients.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR33.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.